title: Comparative study of endralazine and hydralazine for the treatment of hypertension uncontrolled by a beta-blocker and diuretic.
abstract: Endralazine and hydralazine were compared in a randomized double-blind, parallel group study lasting 1 year in 30 patients with essential hypertension inadequately controlled by a beta-blocker and a diuretic. Dosage ranged from 10 mg to 30 mg endralazine per day and from 75 mg to 200 mg hydralazine per day according to patient response. The results showed that endralazine was at least as effective as hydralazine in reducing blood pressure. Patients' tolerance, assessed by drop-out rate, was significantly better (p less than 0.05) in the endralazine group. No cases were found of drug-induced lupus-like syndrome on endralazine as opposed to 2 cases with hydralazine. The dose of endralazine required much less adjustment than that of hydralazine.
authors.forename: B I
authors.initials: BI
authors.lastname: Chazan
authors.forename: D A
authors.initials: DA
authors.lastname: Duff
authors.forename: A
authors.initials: A
authors.lastname: McCallum
authors.forename: K
authors.initials: K
authors.lastname: Whaley
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D000974:Antibodies, Antinuclear / Q000032:analysis; D004232:Diuretics / Q000627:therapeutic use; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006830:Hydralazine / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011724:Pyridazines / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D011897:Random Allocation
chemical_list: D000319:Adrenergic beta-Antagonists; D000974:Antibodies, Antinuclear; D004232:Diuretics; D011724:Pyridazines; D006830:Hydralazine; C014926:BQ 22-708